Key result
Higher adiponectin is linked to ~61% lower pre-diabetes risk in healthy young individuals.
Why the study?
Adiponectin plays an important role in glucose metabolism, but its effect on pre-diabetes and newly diagnosed diabetes across diverse population groups needed exploration.
Are higher adiponectin levels associated with a reduced risk of pre-diabetes and diabetes in specific population subgroups?
Cross-Sectional (n=3,300)
Are higher adiponectin levels associated with a reduced risk of pre-diabetes and diabetes in specific population subgroups?
Odds Ratio: 0.39 (95% CI 0.2–0.73)
Higher adiponectin levels are independently associated with a lower risk of pre-diabetes in young-healthy individuals and a lower risk of diabetes in obese individuals.
Adiponectin patterns across pre-diabetes clusters may aid stratification; leaves open predictive value pending validation studies.
OBJECTIVE: Adiponectin is an adipocyte-derived hormone with an important role in glucose metabolism. The present study explored the effect of adiponectin in diverse population groups on pre-diabetes and newly diagnosed diabetes. METHODS: A total of 3300 individuals were enrolled and their data were collected in the analyses dataset from December 2018 to October 2019. Cluster analysis was conducted based on age, BMI, waistline, body fat, systolic blood pressure, triglycerides, and glycosylated hemoglobin 1c. Cluster analysis divided the participants into four groups: a young-healthy group, an elderly-hypertension group, a high glucose-lipid group, and an obese group. Odds ratio (OR) and 95% CIs were calculated using multivariate logistic regression analysis. RESULTS: Compared with the first quartile of adiponectin, the risk of pre-diabetes of fourth quartile was decreased 61% (aOR = 0.39, 95% CI (0.20-0.73)) in the young-healthy group; and the risk of diabetes of fourth quartile was decreased 85% (aOR = 0.15, 95% CI (0.02-0.67)) in the obese group. There were no significant correlations between the adiponectin level and diabetes/pre-diabetes in the other two groups. Additionally, receiver operating characteristic curve analysis indicated that adiponectin could significantly improve the diagnosis based on models in the young-healthy group (from 0.640 to 0.675) and the obese group (from 0.714 to 0.761). CONCLUSIONS: Increased adiponectin levels were associated with decreased risk of pre-diabetes in the young-healthy population, and with a decreased the risk of diabetes in the obese population. An increased adiponectin level is an independent protective factor for pre-diabetes and diabetes in a specific population in south China.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted a cross-sectional in Pre-diabetes and diabetes (n=3,300). Adiponectin vs. First quartile of adiponectin was evaluated on Risk of pre-diabetes in the young-healthy group (aOR 0.39, 95% CI 0.20-0.73). Higher adiponectin levels (fourth vs first quartile) were associated with a decreased risk of pre-diabetes in young-healthy individuals (aOR 0.39; 95% CI 0.20-0.73).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: